There is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, according to a source cited by Reuters. The news agency reported today that a senior figure close to the matter said: "There is no deal between ​[AZ] and BMS. There never was a deal to be ​done, and there are no discussions between the companies." It has insisted it can achieve that with its internal operations, without a large-scale M&A deal. Photo by Hartono Creative Studio on Unsplash